Proteios Technology

Proteios Technology is a private, pre-revenue biotech firm based in Seattle, WA, with roots in technology developed at the University of Washington. The company is advancing a proprietary device for reversible, multi-marker cell isolation, activation, transduction, and expansion, aiming to address critical bottlenecks in cell therapy development. With a seasoned leadership team and recent non-dilutive grant funding, Proteios is positioning itself as a potential enabler for more efficient and scalable cellular therapeutic production. Its current activities appear focused on platform development and research collaborations, rather than developing its own therapeutic pipeline.

Proprietary device for reversible, label-free, multi-marker cell isolation, activation, transduction, and expansion in a closed system. Originally based on an affinity-based protein purification technology.

Proteios competes in the cell isolation market dominated by large players like Miltenyi Biotec (MACS), Thermo Fisher, and Bio-Rad (flow cytometry). Its key differentiation is the combination of multi-marker selection, a label-free output, and integrated processing steps, which is not offered by current standard technologies.